SAN DIEGO, CA / CRWEPRESSRELEASE / August 12, 2015 /Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTCMKTS:NBIO), is pleased to release a recent interview with company President Sean Carrick, on The Stock Radio show. It can be heard in full at: http://thestockradio.com/otcpink-nbio-nascent-biotech-inc-president-sean-carrick-2239.html
In the interview, Mr. Carrick details that Nascent Biotech’s primary asset, Pritumumab, binds to a very unique target found in epithelial cancers and that they are first focusing on the underserved Brain Cancer patient population. He further explains that it has the potential to be a platform therapy.
Included in the discussion are significant milestones achieved by the company in a relatively short period of time:
- $2.1 million raised since March 2014 which has been used to advance the development of the Pritumumab.
- Manufacturing to clinical grade product in sufficient quantity for trials-with more than enough to conduct
- trials in other cancers such as colon and pancreas.
- Completion of toxicology study under FDA guidance providing understanding of the toxic profile
- Orphan Drug Designation for brain cancer. This will give us market exclusivity for a period of 7 years after the drug is approved.
- Future direction of Nascent.
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
SOURCE:Nascent Biotech, Inc.